Pre-Screening

Pre-screening is the informal, preliminary check a clinical trial site runs to gauge whether a prospective participant is likely to meet a study’s inclusion/exclusion criteria, carried out before the protocol’s formal screening visit and before full informed consent. It typically takes the form of a brief phone or in-person interview against a short eligibility checklist, or a review of existing medical records/electronic health record (EHR) data by clinical staff already involved in the patient’s care.

The defining feature of pre-screening is what it is not: it is not yet the protocol-defined screening process, and in most cases it does not require the participant to have signed the study’s informed consent form (ICF). Records-based pre-screening in particular is frequently conducted under a partial waiver of HIPAA authorization for “reviews preparatory to research” (45 CFR §164.512(i)(1)(ii)), or under a broader IRB-approved waiver/alteration of authorization (45 CFR §164.512(i)(1)(i)) — mechanisms that let an investigator identify potentially eligible candidates from PHI already held by the covered entity without first obtaining a signed authorization, provided the IRB or Privacy Board documents that the review meets the Privacy Rule’s applicable criteria and that no PHI is removed from the covered entity’s custody as part of the review itself. A telephone or in-person pre-screening interview instead typically relies on IRB-approved recruitment language and a short verbal-consent-style script, reviewed and approved by the IRB before use, precisely because it happens ahead of the full ICF.

How pre-screening fits into the enrollment funnel

Pre-screening sits at the very start of the participant funnel, ahead of the two steps that follow it:

• Pre-screening — informal eligibility triage via chart review or a brief interview, generally without a signed ICF, used to rule obviously ineligible candidates out (or flag likely-eligible candidates in) before investing site and participant time in a formal visit.
• Formal screening — the protocol-defined screening process proper: the participant signs the informed consent form, then undergoes the protocol’s specified screening procedures (labs, imaging, exams) to confirm eligibility against every inclusion/exclusion criterion.
• Randomization / enrollment — the participant is assigned a subject ID and, in an interventional trial, randomized to study intervention.

A candidate ruled out at the pre-screening stage never enters the trial’s formal screening and enrollment log and is not counted in the trial’s screen failure rate — sites typically track this population separately (a “pre-screen failure” or “not approached/not eligible” log) precisely because these individuals never became documented research participants.

Pre-screening vs. screen failure

These two terms are often confused because both involve a candidate who does not end up randomized, but they describe different stages and different regulatory contexts:

• Pre-screening is a process — an informal, often consent-light or waiver-based eligibility check that happens before the formal screening visit.
• Screen failure is an outcome — the result recorded when a participant who has already signed the ICF and entered the protocol’s formal screening process is subsequently found ineligible, or withdraws, before randomization.

Put simply: a candidate who never signs consent and is ruled out during a records review or brief phone triage is a pre-screening exclusion, not a screen failure. A candidate who signs consent, undergoes protocol-defined screening procedures, and is then found ineligible before randomization is a screen failure. Confusing the two matters operationally — screen failure rates are a standard enrollment metric reported to sponsors and, in many protocols, IRBs; folding undocumented pre-screening exclusions into that count (or leaving genuine screen failures out of it) distorts recruitment-funnel reporting.

Regulatory and privacy considerations

Because pre-screening frequently happens before a signed ICF exists, it sits at the intersection of two separate regulatory regimes that commonly apply to the same activity but are governed by distinct rules:

• The Common Rule / FDA human-subjects regulations (45 CFR Part 46; 21 CFR Parts 50 and 56) govern informed consent to participate in research. Pre-screening interviews and any recruitment scripts used in them are generally reviewed and approved by the IRB before use, even when no ICF is signed at that stage.
• The HIPAA Privacy Rule (45 CFR Part 164, Subpart E) separately governs a covered entity’s use or disclosure of protected health information (PHI) for research purposes. Records-based pre-screening commonly relies on one of the research pathways at 45 CFR §164.512(i): a full or partial waiver/alteration of authorization documented by an IRB or Privacy Board against the Rule’s minimal-risk criteria, or the “reviews preparatory to research” provision, which permits an investigator to review PHI to help design a study or identify potentially eligible candidates without removing PHI from the covered entity, and without the individual’s authorization.

These are two legally distinct approvals. A site running records-based pre-screening needs its process to satisfy the applicable HIPAA pathway (documented by the IRB or Privacy Board) as well as any IRB expectations for how identified candidates are subsequently approached and consented — the HIPAA waiver alone does not authorize contact; it authorizes the records review used to identify candidates.

Examples

• A clinical research coordinator at an academic medical center runs a query against the EHR, under an IRB-approved partial waiver of HIPAA authorization, to identify patients with a relevant diagnosis code and lab value range who might be eligible for an open oncology trial. Patients flagged this way are then contacted using IRB-approved recruitment language; no PHI is disclosed outside the covered entity, and none of these patients has yet signed an ICF. This is pre-screening.
• A study coordinator conducts a five-minute phone call with a candidate who responded to a recruitment flyer, asking a handful of yes/no eligibility questions from an IRB-approved screening script before inviting the candidate to schedule a formal, in-person screening visit. No ICF is signed during the call. This is also pre-screening.

Counter-example

A participant who has already signed the informed consent form and is undergoing the protocol’s formal screening visit — fasting labs, an ECG, a physical exam specified by the protocol — but is then found not to meet an inclusion criterion, is not a pre-screening exclusion. This is a screen failure, because the defining boundary (a signed ICF and entry into the protocol-defined screening process) has already been crossed.